The Czech national registry ATTRA collects data from patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and juvenile idiopathic arthritis, treated with the biologic drugs. ATTRA is a prospective centralized computerized registry of patients with a focus on efficacy, safety, and quality of life data. Abatacept is approved as a second-line agent which can be prescribed after a failure of at least one TNF-alfa inhibitor. Data of patients treated with abatacept has been collected since 2008. A statistical analysis of the group of RA patients treated with abatacept was performed recently. ATTRA registered 162 patients with RA treated with abatacept, the mean age 51.0 ± 12.2 (median 53.1, 19-74 years), the mean duration of the disease was 14 ± 9.1, median 11.3 years (0-41). One hundred thirty patients (80.2 %) were female. The mean DAS28 was at week 0, 5.9 ± 1.1, at week 16, 4.1 ± 1.4, at week 24, 3.8 ± 1.2, at week 36, 3.6 ± 1.3, and at week 52, 3.5 ± 1.2. DAS28 remission was achieved at week 16 in 15.8 %, at week 24 in 10 %, at week 36 in 20.9 %, and at week 2 in 20.8 % of patients. Of those patients with a DAS28 <2.6 (remission) at week 16, 58.3 % remained in remission at the week 52. Of those patients with DAS28 >5.1 (high disease activity) at the week 16, only 41.7 % had DAS >5.1 at week 52. One year on treatment survival was 82 %. Altogether 50 non-serious adverse events (AE) were reported in 36 patients (22 %) and 11 serious AE in 10 patients (6 %) with the most common being infections (31) and skin rashes (5). Just one non-serious allergic reaction was reported. Data from the ATTRA registry confirms a good overall efficacy and safety profile and a very good on drug survival with abatacept.

Department of Internal Medicine 3 Nephrology Rheumatology Endocrinology Faculty of Medicine and Dentistry Palacký University in Olomouc University Hospital Olomouc 1 P Pavlova 6 772 00 Olomouc Czech Republic

Zobrazit více v PubMed

Clin Rheumatol. 2010 Jun;29(6):583-91 PubMed

Arthritis Rheum. 2005 Aug;52(8):2263-71 PubMed

Ann Rheum Dis. 2011 Jul;70(7):1216-22 PubMed

Br J Rheumatol. 1996 Nov;35(11):1101-5 PubMed

Arthritis Rheum. 1983 Nov;26(11):1346-53 PubMed

Arthritis Rheum. 2013 Jan;65(1):28-38 PubMed

Nat Rev Rheumatol. 2012 Jan 10;8(2):65-6 PubMed

Arthritis Rheum. 2006 Sep;54(9):2807-16 PubMed

Ann Rheum Dis. 2007 Feb;66(2):189-94 PubMed

N Engl J Med. 2003 Nov 13;349(20):1907-15 PubMed

Ther Clin Risk Manag. 2006 Dec;2(4):365-75 PubMed

BMJ. 1993 May 29;306(6890):1437-40 PubMed

Ann Rheum Dis. 2008 Aug;67(8):1096-103 PubMed

WHO Chron. 1969 Jun;23(6):256-63 PubMed

Ann Rheum Dis. 2009 Apr;68(4):484-9 PubMed

Ann Rheum Dis. 2011 Oct;70(10):1826-30 PubMed

Arthritis Rheum. 1996 Jan;39(1):34-40 PubMed

N Engl J Med. 2005 Sep 15;353(11):1114-23 PubMed

J Exp Med. 1991 Sep 1;174(3):561-9 PubMed

Health Policy. 1990 Dec;16(3):199-208 PubMed

Arthritis Rheum. 1995 Jan;38(1):44-8 PubMed

Ann Intern Med. 2006 Jun 20;144(12):865-76 PubMed

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD008794 PubMed

Arthritis Rheum. 2010 Jan;62(1):22-32 PubMed

EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis

Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project